TABLE 2.
Unadjusted Medication Adherence and Duration of First-Line Therapy
| All (N = 3,888) | Latanoprost (n = 1,296) | Travoprost (n = 1,296) | Bimatoprost (n = 1,296) | P Valuea (Latanoprost vs. Travoprost) | P Valuea (Latanoprost vs. Bimatoprost) | P Valuea (Travoprost vs. Bimatoprost) | |
|---|---|---|---|---|---|---|---|
| MPR, mean ± SDb | 47.3 ± 26.7 | 50.1 ± 26.8 | 48.8 ± 26.8 | 43.0 ± 26.1 | 0.179 | < 0.0001 | < 0.0001 |
| Adherence status, n (%)c,d | |||||||
| Adherent | 554 (14.3) | 205 (15.8) | 203 (15.7) | 146 (11.3) | 0.913 | 0.001 | 0.001 |
| Nonadherent | 3,334 (85.8) | 1,091 (84.2) | 1,093 (84.3) | 1,150 (88.7) | |||
| Duration of first-line therapy (days),b,e mean ± SD | 358.4 ± 236.1 | 371.5 ± 249.3c | 360.7 ± 235.0 | 342.9 ± 222.4 | 0.239 | 0.003 | 0.046 |
aSignificant at P < 0.05 (in bold).
bPaired t-test.
cMcNemar’s test.
dAdherence was defined as ≥ 80% MPR.
eTime from initiation of PGA to discontinuation of therapy.
MPR = medication possession ratio; PGA = prostaglandin analog; SD = standard deviation.